Hematological Parameters in the Diagnosis and Treatment of COVID-19

Year 2020, COVID-19Special Issue, 123 - 127, 30.04.2020

Mehmet Fatih Orhan Mustafa Büyükavcı

https://doi.org/10.34084/bshr.718051

Cited By: 1

Abstract

COVID-19’un Tanı ve Tedavi Sürecinde Hematolojik Parametreler

Abstract

COVID-19 tanısı alan hastaların tanı ve tedavi sürecinde gözlenen hematolojik parametrelerin, güncel literatür ışığında incelenmesi amaçlanmıştır. En sık yapılan test olan hemogramda görülebilecek bulgular: Lenfopeni, lökopeni/lökositoz, nötrofili, monositoz, trombositopeni/trombositoz’dur. Koagülasyon parametrelerinden de PT uzunluğu, D-Dimer yüksekliği ve fibrinojen yüksekliği rapor edilen bulgulardandır. Dissemine intravasküler koagülasyon ortaya çıkma ihtimali nedeniyle de düşük molekül ağırlıklı heparin kullanımı gündeme gelmiştir. Tedavi algoritmalarında şu an kullanılmakta olan ve kullanılması olası etken maddelerin tüm hematolojik yan etkileri de özetlenmiştir. Önümüzdeki aylarda/yıllarda insanoğlunun henüz 3 aylık süredir tanıdığı bu SARS-CoV-2 virüsünün oluşturduğu hastalık hakkında bilgisi artmaya devam edecektir.

Keywords

Covid-19, SARS-CoV-2, Hematolojik Testler

References

• 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
• 2. Sun D, Li H, Lu XX, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. World J Pediatr. 2020.
• 3. Shen Q, Guo W, Guo T, et al. Novel coronavirus infection in children outside of Wuhan, China. Pediatr Pulmonol. 2020.
• 4. Chng WJ, Lai HC, Earnest A, Kuperan P. Haematological parameters in severe acute respiratory syndrome. Clin Lab Haematol. 2005;27(1):15-20.
• 5. Fan BE, Chong VCL, Chan SSW, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020.
• 6. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res. 2020;21(1):74.
• 7. Mardani R, Ahmadi Vasmehjani A, Zali F, et al. Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study. Arch Acad Emerg Med. 2020;8(1):e43.
• 8. Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. Ann Palliat Med. 2020.
• 9. Li YY, Wang WN, Lei Y, et al. [Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E023.
• 10. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020.
• 11. Zhang MQ, Wang XH, Chen YL, et al. [Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):215-218.
• 12. Li YX, Wu W, Yang T, et al. [Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19]. Zhonghua Nei Ke Za Zhi. 2020;59(0):E003.
• 13. Qu R, Ling Y, Zhang YH, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020.
• 14. Wan S, Xiang Y, Fang W, et al. Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing. J Med Virol. 2020.
• 15. Li CX, Wu B, Luo F, Zhang N. [Clinical Study and CT Findings of a Familial Cluster of Pneumonia with Coronavirus Disease 2019 (COVID-19)]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2020;51(2):155-158.
• 16. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020.
• 17. Zhang Y, Cao W, Xiao M, et al. [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(0):E006.
• 18. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020.
• 19. Liu M, He P, Liu HG, et al. [Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):209-214.
• 20. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020:105938.
• 21. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020:105932.
• 22. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73.
• 23. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271.
• 24. Dholaria B, Savani BN. How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat? Br J Haematol. 2020.